Clinical trials: Chronic Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease
Symbicort in Chronic Obstructive Pulmonary Disease
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine…
- Trial name
- SYMBOL (NCT00611520)
- Volunteers
- 64,730 people
- Sponsor
- AstraZeneca
Obesity, COPD
Evaluation of Muscle Activation Efficiency in Challenging Subjects
The purpose of this study is to determine whether muscle activation can be accomplished more effectively and comfortably in challenging subjects using novel configurations of an activation device.
- Trial name
- NCT01811446
- Testing
- Muscle Activation with Niveus and Intelect Devices
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Niveus Medical, Inc.
Asthma, Chronic Obstructive Pulmonary Disease
Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease
The study is to evaluate the percentage of patients with asthma or COPD achieving disease control
- Trial name
- SPRINT (NCT02419872)
- Testing
- Marketed antagonists
- Where
- 141 sites in Croatia, Denmark and 8 more
- Volunteers
- 1,743 people
- Sponsor
- Teva Pharmaceuticals Europe
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
A Clinical Evaluation of the RheOx Bronchial Rheoplasty System
This is a prospective, multicenter, single arm and open-label clinical trial to evaluate the performance, effectiveness and safety of RheOx™ system in the treatment of the symptoms of chronic bronchitis in adult moderate to…
- Trial name
- NCT05641207
- Testing
- RheOx™ with the RheOx™ Catheter treated in the trial
- Where
- 7 sites in China
- Volunteers
- 40 people
- Sponsor
- Energenx Medical LTD.
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Medlink for Diagnosing of Diabetes Mellitus, COPD, CHF, Myasthenia Gravis and Hypertension
MEDLINK IS A POCKET-SIZED MEDLINK is a pocket-sized, verbally interactive, programmable medical device that allows physicians to select which medical measurements they would like to take for a specific patient.
- Conditions
- Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Myasthenia Gravis
- Trial name
- Medlink (NCT06256172)
- Testing
- Medlink
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Olawuyi Racett Nigeria Ltd
Pulmonary Disease, Chronic Obstructive
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
This is a randomised study to be conducted in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients to be continuously treated with an inhaled…
- Trial name
- NCT00975195
- Testing
- tiotropium inhalation, salmeterol xinafoate, fluticasone propionate
- Where
- 222 sites in Australia, Belgium and 21 more
- Volunteers
- 2,488 people
- Sponsor
- Boehringer Ingelheim
Chronic Bronchitis
Gala FIH Feasibility Study for the Treatment of Chronic Bronchitis
Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis.
- Trial name
- NCT03107494
- Testing
- Gala Airway Treatment System
- Where
- 2 sites in Austria, Chile
- Volunteers
- 18 people
- Sponsor
- Gala Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events
Background: Recent observational studies have reported possible arrhythmogenic effects with long-acting beta-agonists (LABA), while the long-acting anticholinergic tiotropium has been associated with cardiovascular and…
- Trial name
- NCT02096731
- Where
- Canada
- Volunteers
- 115,397 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered…
- Trial name
- NCT00400153
- Testing
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg)
- Where
- 180 sites in United States, Argentina and 11 more
- Volunteers
- 1,480 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)
The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine…
- Trial name
- NCT03165045
- Testing
- Spiolto® Respimat®
- Where
- 108 sites in Germany
- Volunteers
- 1,351 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, COPD
Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD
A study multicenter, phase III, randomized, open label study to evaluate the efficacy and safety of a fixed-dose combination of formoterol/fluticasone and salmeterol/fluticasone in patients with moderate-to-severe chronic…
- Trial name
- NCT01393145
- Testing
- Combination Fluticasone /Formoterol 12/250 μg, Seretide Diskus (salmeterol/fluticasone) 50/250 μg
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
COPD
Effects of Ergometer Training With Telemonitoring in Patients With Chronic Obstructive Pulmonary Disease (COPD) After Exacerbation
Home ergometer training combined with online monitoring and regular telephone support could prove to be a cost-effective method to improve physical performance and quality of life in COPD patients.
- Trial name
- COPD (NCT01987544)
- Testing
- Ergometer Training, Motivation
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Chronic Obstructive Lung Disease
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal
The purpose of this study s to determine whether treatment with Iodinated Active Charcoal can improve lung function and physical capacity in patients with chronic obstructive lung disorders.
- Trial name
- NCT01404000
- Testing
- Iodinated Active Charcoal (IodoCarb)
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- PharmaLundensis AB
COPD
Drug-drug Interaction Study of CHF5993 With Cimetidine
The purpose of this study is to evaluate the pharmacokinetic interaction when CHF5993 (pressurized metered-dose inhaler (pMDI) is administered with Cimetidine (probe inhibitor of the organic cation transport in the kidneys), by…
- Trial name
- NCT02287272
- Testing
- CHF 5993 pMDI, Cimetidine plus CHF5993 pMDI
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT04542057
- Testing
- Ensifentrine
- Where
- 130 sites in United States, Belgium and 8 more
- Volunteers
- 790 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The compound GW642444 has previously been found to be well tolerated with no significant side effects in subjects with asthma and healthy volunteers.
- Trial name
- NCT00372112
- Testing
- GW642444
- Where
- 14 sites in Australia, Bulgaria and 4 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder and GW642444 Inhalation Powder via a Novel Dry…
- Trial name
- NCT01316900
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444
- Where
- 97 sites in United States, France and 8 more
- Volunteers
- 846 people
- Sponsor
- GlaxoSmithKline
Croup, Bronchiolitis
A Study Evaluating the Use of ResAppDx v2.0 as an Aid to Diagnose Respiratory Disease in Paediatric Patients in an Emergency Department
Aim of study is to demonstrate that the ResAppDx v2.0 algorithms provide an accurate diagnosis of paediatric respiratory disease in the study's clinical setting compared to a Clinical Adjudication Committee's (CAC) diagnosis; and…
- Conditions
- Croup, Bronchiolitis, Asthma in Children, Reactive Airway Disease
- Trial name
- NCT06156436
- Testing
- ResAppDx v.20
- Where
- 5 sites in United Kingdom
- Volunteers
- 75 people
- Sponsor
- ResApp Health Limited
Pulmonary Disease, Chronic Obstructive
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Study to evaluate the safety of combivent delivered in two different formulations (hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI), using a cumulative dose response model in patients with…
- Trial name
- NCT02182869
- Testing
- Combivent® HFA inhalation aerosol, Combivent® CFC inhalation aerosol
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients
The purpose of this study is to evaluate the efficacy and safety of CHF 5259 (glycopyrrolate bromide) for the treatment of COPD patients.
- Trial name
- Trigon (NCT02189577)
- Testing
- CHF 5259
- Where
- 29 sites in Bulgaria, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.